← Back to patent-cliff list
Leniolisib phosphate
Tier C — Watch / tradeLeniolisib phosphate
Novartis
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PI3Kδ
Brand：JOENJA
Indications (approved)：原发性免疫缺陷疾病, PI3Kδ过度活化综合征
Regional status
US
Approved
2023-03-24
EU
Approved
2026-05-21
China
-
Japan
Approved
2026-03-23
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Leniolisib phosphate?
Approved indications include: 原发性免疫缺陷疾病, PI3Kδ过度活化综合征.
When does the Leniolisib phosphate patent expire?
No public expiry year is available for Leniolisib phosphate yet; this page updates once verified.
How do I get a quote for Leniolisib phosphate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27